Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 3 records in total 3
    records per page

    Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding

    Authors: DM Shalimar; Manas Vaishnav; Anshuman Elhence; Ramesh Kumar; Srikant Mohta; Chandan Palle; Peeyush Kumar; Mukesh Ranjan; Tanmay Vajpai; Shubham Prasad; Jatin Yegurla; Anugrah Dhooria; Vikas Banyal; Samagra Agarwal; Rajat Bansal; Sulagna Bhattacharjee; Richa Aggarwal; Kapil D Soni; Swetha Rudravaram; Ashutosh K Singh; Irfan Altaf; Avinash Choudekar; Soumya J Mahapatra; Deepak Gunjan; Saurabh Kedia; Govind Makharia; Anjan Trikha; Pramod Garg; Anoop Saraya

    doi:10.1101/2020.08.06.20169813 Date: 2020-08-07 Source: medRxiv

    Background: There is a paucity of data on the management of gastrointestinal(GI) bleeding MESHD in patients with COVID-19 amid concerns about the risk of transmission TRANS during endoscopic procedures.We aimed to study the outcomes of conservative treatment for GI bleeding MESHD in patients with COVID-19. Methods: In this retrospective analysis, 24 of 1342(1.8%) patients with COVID-19, presenting with GI bleeding MESHD from 22ndApril to 22ndJuly 2020, were included. Results: The mean age TRANS of patients was 45.8+/-12.7 years; 17(70.8%) were males TRANS; upper GI(UGI) bleeding MESHD: lower GI MESHD(LGI) 23:1. Twenty-two(91.6%) patients had evidence of cirrhosis HP cirrhosis MESHD- 21 presented with UGI bleeding MESHD while one had bleeding MESHD from hemorrhoids HP hemorrhoids MESHD. Two patients without cirrhosis HP cirrhosis MESHD were presumed to have non-variceal bleeding MESHD. The medical therapy for UGI bleeding included vasoconstrictors- somatostatin in 17(73.9%) and terlipressin in 4(17.4%) patients. All patients with UGI bleeding MESHD received proton pump inhibitors and antibiotics. Packed red blood SERO cells(PRBCs), fresh frozen plasma SERO and platelets were transfused in 14(60.9%), 3(13.0%) and 3(13.0%), respectively. The median PRBCs transfused was 1(0-3) unit(s). The initial control of UGI bleeding MESHD was achieved in all 23 patients and none required an emergency endoscopy. At 5-day follow-up, none rebled or died. Two patients later rebled, one had intermittent bleed due to gastric antral vascular ectasia MESHD, while another had rebleed 19 days after discharge. Three(12.5%) cirrhosis HP cirrhosis MESHD patients succumbed to acute hypoxemic respiratory failure MESHD respiratory failure HP during hospital stay. Conclusion: Conservative management strategies including pharmacotherapy, restrictive transfusion strategy, and close hemodynamic monitoring can successfully manage GI bleeding MESHD in COVID-19 patients and reduce need for urgent endoscopy.

    Clinical Characteristics Hospitalized Patients with SARS-Cov-2 and HBV Co-infection MESHD

    Authors: Xiaoping Chen; Qunqun Jiang; Zhiyong Ma; Jiaxin Ling; Wenjia Hu; Qian Cao; Pingzheng Mo; Rongrong Yang; Shicheng Gao; Xien Gui; Yong Xiong; Jinlin Li; Yongxi Zhang

    doi:10.1101/2020.03.23.20040733 Date: 2020-03-27 Source: medRxiv

    Background & Aims The coronavirus disease MESHD 2019 (COIVD-19) caused by SARS-CoV-2 has been characterized as a pandemic, which causes a serious public health challenge in the world. A very large group of patients infected by HBV has been reported worldwide, especially in China. In order to answer whether specific treatment strategy on the patients coinfected with HBV and SARS-CoV-2, it requires profound understanding of the clinical characteristics on those patients. However, the impacts of SARS-CoV-2 infection MESHD on HBV patients remain largely unknown. Approach & Results In this retrospective investigation, we included 123 COVID-19 patients admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to March 7, 2020. All enrolled patients are the laboratory confirmed COVID-19 pneumonia HP pneumonia MESHD cases according to the criteria reported previously. A total of 123 patients were analyzed for their Clinical records, laboratory results including the diagnosis of HBV infection MESHD and liver function. Among 123 confirmed COVID-19 patients, the mean age TRANS was 51 years old and 59.3% were females TRANS (73/123). Fifteen were previously HBV infected MESHD patients, 66.7% of them were males TRANS (10/15), patients with HBV infection MESHD appeared to have a higher incidence of liver cirrhosis MESHD cirrhosis HP and an increased level of total bilirubin. Seven (46.7%) patients with HBV infection MESHD were defined as severe cases, while the severity rate was 24.1% for the patients without HBV infection MESHD (26/108). The mortality of patients with HBV infection MESHD was 13.3% (2/15) compared to 2.8% (3/108) for the patients without HBV infection MESHD. Conclusions SARS-CoV-2 infection MESHD may cause liver function damage MESHD in COVID-19 cases and the patients with HBV infection MESHD are likely to have more severe disease outcome.

    Pathological Study of the 2019 Novel Coronavirus Disease MESHD (COVID-19) through Post-Mortem Core Biopsies

    Authors: Sufang Tian; Yong Xiong; Huan Liu; Li Niu; Jianchun Guo; Meiyan Liao; Shu-Yuan Xiao

    id:10.20944/preprints202003.0311.v1 Date: 2020-03-20 Source:

    Data on pathologic changes of the 2019 novel coronavirus disease MESHD (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed post-mortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia HP pneumonia MESHD. The patients’ ages TRANS ranged from 59 to 81, including 3 males TRANS and 1 female TRANS. Each patient had at least one underlying disease, including immunocompromised status ( chronic lymphocytic leukemia MESHD leukemia HP and renal transplantation) or other conditions ( cirrhosis HP cirrhosis MESHD, hypertension HP hypertension MESHD, and diabetes MESHD). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood SERO cell counts, with significant rise toward the end, and all had lymphocytopenia MESHD except for the patient with leukemia HP leukemia MESHD. Histologically, the main findings are in the lungs, including injury to the alveolar MESHD epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes MESHD, all components of diffuse alveolar damage MESHD. Consolidation by fibroblastic proliferation with extracellular matrix and fibrin forming clusters in airspaces is evident. In one patient, the consolidation consists of abundant intra-alveolar neutrophilic infiltration MESHD, consistent with superimposed bacterial bronchopneumonia MESHD. The liver exhibits mild lobular infiltration by small lymphocytes, and centrilobular sinusoidal dilation. Patchy necrosis is also seen. The heart shows only focal mild fibrosis MESHD and mild myocardial hypertrophy MESHD, changes likely related to the underlying conditions. In conclusion, the post-mortem examinations show advanced diffuse alveolar damage MESHD, as well as superimposed bacterial pneumonia HP pneumonia MESHD in some patients. Changes in the liver and heart are likely secondary or related to the underlying diseases.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.